Article(id=1222469715327443493, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1222469705873481976, articleNumber=null, orderNo=null, doi=10.16438/j.0513-4870.2019-0563, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=research-article, receivedDate=1563206400000, receivedDateStr=2019-07-16, revisedDate=1567612800000, revisedDateStr=2019-09-05, acceptedDate=null, acceptedDateStr=null, onlineDate=1769389092522, onlineDateStr=2026-01-26, pubDate=1570809600000, pubDateStr=2019-10-12, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1769389092522, onlineIssueDateStr=2026-01-26, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1769389092522, creator=13701087609, updateTime=1769389092522, updator=13701087609, issue=Issue{id=1222469705873481976, tenantId=1146029695717560320, journalId=1189982191388893191, year='2019', volume='54', issue='10', pageStart='1711', pageEnd='1880', issueExtLink='null', onlineDate='null', pubDate='1570809600000', pubDateStr='2019-10-12', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1769389090269, creator='13701087609', updateTime=1769389551199, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1222471639254683958, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1222469705873481976, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1222471639254683959, tenantId=1146029695717560320, journalId=1189982191388893191, issueId=1222469705873481976, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1810, endPage=1817, ext={EN=ArticleExt(id=1222469715864314452, articleId=1222469715327443493, tenantId=1146029695717560320, journalId=1189982191388893191, language=EN, title=Advanced research and technology development of antibody-drug conjugates, columnId=1190335348648547107, journalTitle=Acta Pharmaceutica Sinica, columnName=Reviews, runingTitle=null, highlight=null, articleAbstract=

Although numbers of naked antibodies showing clinical efficacy as single agents, their therapeutic effect is limited. Chemotherapy is very effective but with relatively large side effects, so conjugation of small chemotherapeutic drugs to antibodies is one of the important methods to enhance therapeutic potential of antibodies. Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. These modified antibodies are expected to selectively deliver chemotherapeutic drugs to tumor cells and provide sustained clinical benefit to cancer patients, at the same time, minimizing systemic toxicity. ADCs are expected to bring together the benefits of highly potent drugs on the one hand and selective binders of specific tumor antigens on the other hand. However, designing an ADC is very complex, requiring thoughtful combination of antibody, linker, and payload drugs in the context of a target and a defined cancer indication. Although many challenges remain, recent clinical success has generated intense interest in this therapeutic class.

, authors=null, authorsList=Hong-bin SONG, Dong-lian LIU, Peng-fei LI, Ji-dong ZHAO, Yan-fei QU, authorCompany=null, correspAuthors=Hong-bin SONG, authorNote=null, correspAuthorsNote=null, copyrightStatement=Copyright ©2019 Acta Pharmaceutica Sinica. All rights reserved., copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1222469716690592386, articleId=1222469715327443493, tenantId=1146029695717560320, journalId=1189982191388893191, language=CN, title=抗体偶联药物发展与进展, columnId=1190335349655180086, journalTitle=药学学报, columnName=综述, runingTitle=null, highlight=null, articleAbstract=

许多单克隆抗体药物作为单一药物虽然显示出一定临床治疗效果，但其治疗效果不佳，而化疗药物疗效较强，其毒副作用也较大，如在单克隆抗体上化学偶联上小分子化学药物，是提高抗体药物疗效的重要方法之一。抗体偶联药物是由抗原特异性靶向作用的单克隆抗体和高活性细胞毒类化学药物偶联而成，是一种很有潜力的新型肿瘤治疗靶向药物。这类修饰抗体能够通过抗体部分特异性结合癌细胞表位的抗原而选择性地将高活性细胞毒药物运送到肿瘤细胞内，这将使癌症患者治疗疗效最大化，药物全身毒副作用最小化。抗体偶联药物能够协同发挥抗体的"特异性"靶向作用和高活性细胞毒类药物"高效"癌细胞杀伤作用。然而，抗体偶联药物的分子设计非常复杂，针对癌细胞不同靶点和药物适应症，需要同时充分考虑抗体、链接子和载荷药物的不同组合选择，尽管该类药物还存在诸多挑战，但最近临床研究的成功促使抗体偶联药物越来越受到极大关注和兴趣。

, authors=null, authorsList=宋洪彬, 刘冬连, 李鹏飞, 赵季冬, 曲妍霏, authorCompany=null, correspAuthors=宋洪彬, authorNote=null, correspAuthorsNote=, copyrightStatement=版权所有©《药学学报》编辑部2019, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=dHeyAMII2t3F5nRiR/YVEA==, magXml=aF9L2ABxifgZU5emQFxOdA==, pdfUrl=null, pdf=leNt2v9Ch0sf742r6rEwiA==, pdfFileSize=863138, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=PslrqQaCv0mwhvMI0WX6dg==, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=ZqVub4GTF3NN7ip2xE3ILw==, mapNumber=null, fund=null)}, authors=[Author(id=1222469717005165214, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=shbwl123@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1222469717130994345, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469717005165214, language=EN, stringName=Hong-bin SONG, firstName=Hong-bin, middleName=null, lastName=SONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^*, address=TOT Biopharm, Suzhou 215123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1222469717210686125, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469717005165214, language=CN, stringName=宋洪彬, firstName=洪彬, middleName=null, lastName=宋, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=^*, address=东曜药业有限公司, 江苏 苏州 215123, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1222469716904501905, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, xref=null, ext=[AuthorCompanyExt(id=1222469716912890514, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=TOT Biopharm, Suzhou 215123, China), AuthorCompanyExt(id=1222469716917084819, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=东曜药业有限公司, 江苏 苏州 215123)])]), Author(id=1222469717294572211, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1222469717407818426, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469717294572211, language=EN, stringName=Dong-lian LIU, firstName=Dong-lian, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=TOT Biopharm, Suzhou 215123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1222469717512676032, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469717294572211, language=CN, stringName=刘冬连, firstName=冬连, middleName=null, lastName=刘, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=东曜药业有限公司, 江苏 苏州 215123, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1222469716904501905, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, xref=null, ext=[AuthorCompanyExt(id=1222469716912890514, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=TOT Biopharm, Suzhou 215123, China), AuthorCompanyExt(id=1222469716917084819, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=东曜药业有限公司, 江苏 苏州 215123)])]), Author(id=1222469717659476681, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1222469717793694416, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469717659476681, language=EN, stringName=Peng-fei LI, firstName=Peng-fei, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=TOT Biopharm, Suzhou 215123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1222469717898552022, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469717659476681, language=CN, stringName=李鹏飞, firstName=鹏飞, middleName=null, lastName=李, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=东曜药业有限公司, 江苏 苏州 215123, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1222469716904501905, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, xref=null, ext=[AuthorCompanyExt(id=1222469716912890514, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=TOT Biopharm, Suzhou 215123, China), AuthorCompanyExt(id=1222469716917084819, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=东曜药业有限公司, 江苏 苏州 215123)])]), Author(id=1222469717978243806, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1222469718074712803, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469717978243806, language=EN, stringName=Ji-dong ZHAO, firstName=Ji-dong, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=TOT Biopharm, Suzhou 215123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1222469718166987498, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469717978243806, language=CN, stringName=赵季冬, firstName=季冬, middleName=null, lastName=赵, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=东曜药业有限公司, 江苏 苏州 215123, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1222469716904501905, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, xref=null, ext=[AuthorCompanyExt(id=1222469716912890514, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=TOT Biopharm, Suzhou 215123, China), AuthorCompanyExt(id=1222469716917084819, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=东曜药业有限公司, 江苏 苏州 215123)])]), Author(id=1222469718242484976, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1222469718343148281, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469718242484976, language=EN, stringName=Yan-fei QU, firstName=Yan-fei, middleName=null, lastName=QU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=TOT Biopharm, Suzhou 215123, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1222469718456394492, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, authorId=1222469718242484976, language=CN, stringName=曲妍霏, firstName=妍霏, middleName=null, lastName=曲, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=东曜药业有限公司, 江苏 苏州 215123, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1222469716904501905, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, xref=null, ext=[AuthorCompanyExt(id=1222469716912890514, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=TOT Biopharm, Suzhou 215123, China), AuthorCompanyExt(id=1222469716917084819, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=东曜药业有限公司, 江苏 苏州 215123)])])], keywords=[Keyword(id=1222469718569640705, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=EN, orderNo=1, keyword=antibody-drug conjugate), Keyword(id=1222469718666109700, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=EN, orderNo=2, keyword=cytotoxic compound), Keyword(id=1222469718737412870, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=EN, orderNo=3, keyword=linker), Keyword(id=1222469718833881866, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=EN, orderNo=4, keyword=payload), Keyword(id=1222469718926156560, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=CN, orderNo=1, keyword=抗体偶联药物), Keyword(id=1222469719026819860, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=CN, orderNo=2, keyword=细胞毒素), Keyword(id=1222469719114900243, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=CN, orderNo=3, keyword=链接子), Keyword(id=1222469719194592023, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=CN, orderNo=4, keyword=载荷药物)], refs=[Reference(id=1222469720243168069, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1038/nrd2241, pmid=null, pmcid=null, year=2007, volume=6, issue=null, pageStart=349, pageEnd=356, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=Janice MR, Viia EVR, journalName=Nat Rev Drug Dis, refType=null, unstructuredReference= Janice MR , Viia EVR . Development trends for monoclonal antibody cancer therapeutics[J]. Nat Rev Drug Dis, 2007, 6: 349-356., articleTitle=Development trends for monoclonal antibody cancer therapeutics, refAbstract=null), Reference(id=1222469720331248457, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1038/256495a0, pmid=null, pmcid=null, year=1975, volume=256, issue=null, pageStart=495, pageEnd=497, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=Kohler G, Milstein C, journalName=Nature, refType=null, unstructuredReference= Kohler G , Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity[J]. Nature, 1975, 256: 495-497., articleTitle=Continuous cultures of fused cells secreting antibody of predefined specificity, refAbstract=null), Reference(id=1222469720423523150, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=null, pmid=null, pmcid=null, year=2009, volume=525, issue=null, pageStart=1, pageEnd=27, url=http://d.old.wanfangdata.com.cn/NSTLQK/10.1007-978-1-59745-554-1_1/, language=null, rfNumber=[3], rfOrder=2, authorNames=Dimitrov DS, Marks JD, journalName=Methods Mol Biol, refType=null, unstructuredReference= Dimitrov DS , Marks JD . Therapeutic antibodies: current state and future trends is a paradigm change coming soon[J]. Methods Mol Biol, 2009, 525: 1-27., articleTitle=Therapeutic antibodies: current state and future trends is a paradigm change coming soon, refAbstract=null), Reference(id=1222469720536769359, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1038/nrc2394, pmid=null, pmcid=null, year=2008, volume=8, issue=null, pageStart=473, pageEnd=480, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=Strebhardt K, Ullrich A, journalName=Nat Rev Cancer, refType=null, unstructuredReference= Strebhardt K , Ullrich A . Paul Ehrlich's magic bullet concept: 100 years of progress[J]. Nat Rev Cancer, 2008, 8: 473-480., articleTitle=Paul Ehrlich's magic bullet concept: 100 years of progress, refAbstract=null), Reference(id=1222469720637432662, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1007/s40264-018-0775-7, pmid=null, pmcid=null, year=2019, volume=42, issue=null, pageStart=295, pageEnd=314, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=Wolska-Washer A, Robak T, journalName=Drug Saf, refType=null, unstructuredReference= Wolska-Washer A , Robak T . Safety and tolerability of antibody-drug conjugates in cancer[J]. Drug Saf, 2019, 42: 295-314., articleTitle=Safety and tolerability of antibody-drug conjugates in cancer, refAbstract=null), Reference(id=1222469720767456090, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1016/j.cbpa.2009.03.023, pmid=null, pmcid=null, year=2009, volume=13, issue=null, pageStart=235, pageEnd=244, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=Senter PD, journalName=Curr Opin Chem Biol, refType=null, unstructuredReference= Senter PD . Potent antibody drug conjugates for cancer therapy[J]. Curr Opin Chem Biol, 2009, 13: 235-244., articleTitle=Potent antibody drug conjugates for cancer therapy, refAbstract=null), Reference(id=1222469720876507996, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1016/S0952-7915(99)00012-6, pmid=null, pmcid=null, year=1999, volume=11, issue=null, pageStart=584, pageEnd=588, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=Trail PA, Bianchi AB, journalName=Curr Opin Immunol, refType=null, unstructuredReference= Trail PA , Bianchi AB . Monoclonal antibody drug conjugates in the treatment of cancer[J]. Curr Opin Immunol, 1999, 11: 584-588., articleTitle=Monoclonal antibody drug conjugates in the treatment of cancer, refAbstract=null), Reference(id=1222469720977171300, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1007/s11095-015-1729-8, pmid=null, pmcid=null, year=2015, volume=32, issue=null, pageStart=3577, pageEnd=3583, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=Xu S, journalName=Pharm Res, refType=null, unstructuredReference= Xu S . Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates[J]. Pharm Res, 2015, 32: 3577-3583., articleTitle=Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates, refAbstract=null), Reference(id=1222469721065251687, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1007/s10549-010-1090-x, pmid=null, pmcid=null, year=2011, volume=128, issue=null, pageStart=347, pageEnd=356, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=Junttila TT, Li G, Parsons K, journalName=Breast Cancer Res Treat, refType=null, unstructuredReference= Junttila TT , Li G , Parsons K et al . Trastuzumab-dm1 (t-dm1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer[J]. Breast Cancer Res Treat, 2011, 128: 347-356., articleTitle=Trastuzumab-dm1 (t-dm1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer, refAbstract=null), Reference(id=1222469721161720681, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1016/j.ccr.2009.03.020, pmid=null, pmcid=null, year=2009, volume=15, issue=null, pageStart=429, pageEnd=440, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=Junttila TT, Akita RW, Parsons K, journalName=Cancer Cell, refType=null, unstructuredReference= Junttila TT , Akita RW , Parsons K et al . Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941[J]. Cancer Cell, 2009, 15: 429-440., articleTitle=Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941, refAbstract=null), Reference(id=1222469721283355503, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1038/bjc.2017.367, pmid=null, pmcid=null, year=2017, volume=117, issue=null, pageStart=1736, pageEnd=1742, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=Staudacher AH, Brown MP, journalName=Br J Cancer, refType=null, unstructuredReference= Staudacher AH , Brown MP . Antibody drug conjugates and bystander killing: is antigen-dependent internalization required[J]. Br J Cancer, 2017, 117: 1736-1742., articleTitle=Antibody drug conjugates and bystander killing: is antigen-dependent internalization required, refAbstract=null), Reference(id=1222469721358852980, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=null, pmid=null, pmcid=null, year=2014, volume=92, issue=null, pageStart=13, pageEnd=21, url=http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0231959483/, language=null, rfNumber=[12], rfOrder=11, authorNames=Thayer AM, journalName=Chem Eng News, refType=null, unstructuredReference= Thayer AM . Building antibody-drug conjugates[J]. Chem Eng News, 2014, 92: 13-21., articleTitle=Building antibody-drug conjugates, refAbstract=null), Reference(id=1222469721446933367, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1038/nbt.1480, pmid=null, pmcid=null, year=2008, volume=26, issue=null, pageStart=925, pageEnd=932, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=Junutula JR, Raab H, Clark S, journalName=Nat Biotechnol, refType=null, unstructuredReference= Junutula JR , Raab H , Clark S et al . Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index[J]. Nat Biotechnol, 2008, 26: 925-932., articleTitle=Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, refAbstract=null), Reference(id=1222469721564373880, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1093/jnci/djs140, pmid=null, pmcid=null, year=2012, volume=104, issue=null, pageStart=622, pageEnd=634, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=Moldenhauer G, Salnikov AV, Luttgau S, journalName=J Natl Cancer Inst, refType=null, unstructuredReference= Moldenhauer G , Salnikov AV , Luttgau S et al . Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma[J]. J Natl Cancer Inst, 2012, 104: 622-634., articleTitle=Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma, refAbstract=null), Reference(id=1222469721711174525, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1158/0008-5472.CAN-09-3546, pmid=null, pmcid=null, year=2010, volume=70, issue=null, pageStart=2528, pageEnd=2537, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=Kovtun YV, Audette CA, Mayo MF, journalName=Cancer Res, refType=null, unstructuredReference= Kovtun YV , Audette CA , Mayo MF et al . Antibody-maytansinoid conjugates designed to bypass multidrug resistance[J]. Cancer Res, 2010, 70: 2528-2537., articleTitle=Antibody-maytansinoid conjugates designed to bypass multidrug resistance, refAbstract=null), Reference(id=1222469721807643519, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=null, pmid=null, pmcid=null, year=2006, volume=24, issue=null, pageStart=5, pageEnd=10, url=http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=e75a74d0def05e2705e1b93cb1788eb1, language=null, rfNumber=[16], rfOrder=15, authorNames=Farris JP, Ader AW, Ku RH, journalName=Chem Today, refType=null, unstructuredReference= Farris JP , Ader AW , Ku RH . History, implementation and evolution of the pharmaceutical hazard categorization and control system[J]. Chem Today, 2006, 24: 5-10., articleTitle=History, implementation and evolution of the pharmaceutical hazard categorization and control system, refAbstract=null), Reference(id=1222469721929278338, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=null, pmid=null, pmcid=null, year=2009, volume=10, issue=null, pageStart=48, pageEnd=53, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=Ader AW, Kimmel TA, Sussman RG, journalName=Pharm Outsourcing, refType=null, unstructuredReference= Ader AW , Kimmel TA , Sussman RG . Applying health-based risk assessments to worker and product safety for potent pharmaceuticals in contract manufacturing operations[J]. Pharm Outsourcing, 2009, 10: 48-53., articleTitle=Applying health-based risk assessments to worker and product safety for potent pharmaceuticals in contract manufacturing operations, refAbstract=null), Reference(id=1222469722034135943, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1038/nrd.2016.268, pmid=null, pmcid=null, year=2017, volume=16, issue=null, pageStart=315, pageEnd=337, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=Beck A, Goetsch L, Dumontet C, journalName=Nat Rev Drug Discov, refType=null, unstructuredReference= Beck A , Goetsch L , Dumontet C et al . Strategies and challenges for the next generation of therapeutic antibodies[J]. Nat Rev Drug Discov, 2017, 16: 315-337., articleTitle=Strategies and challenges for the next generation of therapeutic antibodies, refAbstract=null), Reference(id=1222469722109633418, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=null, pmid=null, pmcid=null, year=2001, volume=7, issue=null, pageStart=1490, pageEnd=1496, url=https://www.ncbi.nlm.nih.gov/pubmed/11410481, language=null, rfNumber=[19], rfOrder=18, authorNames=Bross PF, Beitz J, Chen G, journalName=Clin Cancer Res, refType=null, unstructuredReference= Bross PF , Beitz J , Chen G et al . Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia[J]. Clin Cancer Res, 2001, 7: 1490-1496., articleTitle=Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia, refAbstract=null), Reference(id=1222469722197713805, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1182/blood-2013-01-466706, pmid=null, pmcid=null, year=2013, volume=121, issue=null, pageStart=4854, pageEnd=4860, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=Petersdorf SH, Kopecky KJ, Slovak M, journalName=Blood, refType=null, unstructuredReference= Petersdorf SH , Kopecky KJ , Slovak M et al . A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia[J]. Blood, 2013, 121: 4854-4860., articleTitle=A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia, refAbstract=null), Reference(id=1222469722285794190, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1182/blood-2013-03-490482, pmid=null, pmcid=null, year=2013, volume=121, issue=null, pageStart=4838, pageEnd=4841, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=Rowe JM, Lowenberg B, journalName=Blood, refType=null, unstructuredReference= Rowe JM , Lowenberg B . Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug[J]. Blood, 2013, 121: 4838-4841., articleTitle=Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug, refAbstract=null), Reference(id=1222469722382263187, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1200/JCO.2015.62.6846, pmid=null, pmcid=null, year=2016, volume=34, issue=null, pageStart=747, pageEnd=755, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=Pollard JA, Loken M, Gerbing RB, journalName=J Clin Oncol, refType=null, unstructuredReference= Pollard JA , Loken M , Gerbing RB et al . CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase Ⅲ children's oncology group trial AAML0531[J]. J Clin Oncol, 2016, 34: 747-755., articleTitle=CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase Ⅲ children's oncology group trial AAML0531, refAbstract=null), Reference(id=1222469722495509400, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1517/14712598.2011.543895, pmid=null, pmcid=null, year=2011, volume=11, issue=null, pageStart=225, pageEnd=234, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=Breccia M, Lo-Coco F, journalName=Expert Opin Biol Ther, refType=null, unstructuredReference= Breccia M , Lo-Coco F . Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy[J]. Expert Opin Biol Ther, 2011, 11: 225-234., articleTitle=Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy, refAbstract=null), Reference(id=1222469722579395484, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1200/JCO.2001.19.13.3244, pmid=null, pmcid=null, year=2001, volume=19, issue=null, pageStart=3244, pageEnd=3254, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=Sievers EL, Larson RA, Stadtmauer EA, journalName=J Clin Oncol, refType=null, unstructuredReference= Sievers EL , Larson RA , Stadtmauer EA et al . Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) with CD33-postive acute myeloid leukemia in first relapse[J]. J Clin Oncol, 2001, 19: 3244-3254., articleTitle=Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) with CD33-postive acute myeloid leukemia in first relapse, refAbstract=null), Reference(id=1222469722659087263, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.2741/4181, pmid=null, pmcid=null, year=2013, volume=18, issue=null, pageStart=1311, pageEnd=1334, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=Cowan AJ, Laszlo GS, Estey EH, journalName=Front Biosci, refType=null, unstructuredReference= Cowan AJ , Laszlo GS , Estey EH et al . Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin[J]. Front Biosci, 2013, 18: 1311-1334., articleTitle=Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin, refAbstract=null), Reference(id=1222469722730390434, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1056/NEJMoa1002965, pmid=null, pmcid=null, year=2010, volume=363, issue=null, pageStart=1812, pageEnd=1821, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=Younes A, Bartlett NL, Leonard JP, journalName=N Engl J Med, refType=null, unstructuredReference= Younes A , Bartlett NL , Leonard JP et al . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas[J]. N Engl J Med, 2010, 363: 1812-1821., articleTitle=Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas, refAbstract=null), Reference(id=1222469722835248039, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1158/1078-0432.CCR-11-0488, pmid=null, pmcid=null, year=2011, volume=17, issue=null, pageStart=6428, pageEnd=6436, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=Katz J, Janik JE, Younes A, journalName=Clin Cancer Res, refType=null, unstructuredReference= Katz J , Janik JE , Younes A . Brentuximab vedotin (SGN-35)[J]. Clin Cancer Res, 2011, 17: 6428-6436., articleTitle=Brentuximab vedotin (SGN-35), refAbstract=null), Reference(id=1222469722923328425, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1200/JCO.2011.38.0410, pmid=null, pmcid=null, year=2012, volume=30, issue=null, pageStart=2183, pageEnd=2189, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=Younes A, Gopal AK, Smith SE, journalName=J Clin Oncol, refType=null, unstructuredReference= Younes A , Gopal AK , Smith SE et al . Results of a pivotal phase Ⅱ study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma[J]. J Clin Oncol, 2012, 30: 2183-2189., articleTitle=Results of a pivotal phase Ⅱ study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, refAbstract=null), Reference(id=1222469723023991722, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1200/JCO.2011.38.0402, pmid=null, pmcid=null, year=2012, volume=30, issue=null, pageStart=2190, pageEnd=2196, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=Pro B, Advani R, Brice P, journalName=J Clin Oncol, refType=null, unstructuredReference= Pro B , Advani R , Brice P et al . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase Ⅱ study[J]. J Clin Oncol, 2012, 30: 2190-2196., articleTitle=Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase Ⅱ study, refAbstract=null), Reference(id=1222469723116266415, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=null, pmid=null, pmcid=null, year=2013, volume=10, issue=null, pageStart=71, pageEnd=73, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=Abraham J, journalName=Community Oncol, refType=null, unstructuredReference= Abraham J . Trastuzumab emtansine in advanced HER2-positive breast cancer[J]. Community Oncol, 2013, 10: 71-73., articleTitle=Trastuzumab emtansine in advanced HER2-positive breast cancer, refAbstract=null), Reference(id=1222469723195958192, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1200/JCO.2009.26.2071, pmid=null, pmcid=null, year=2010, volume=28, issue=null, pageStart=2698, pageEnd=2704, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=Krop I, Beeram M, Modi S, journalName=J Clin Oncol, refType=null, unstructuredReference= Krop I , Beeram M , Modi S et al . A phase Ⅰ study of trastuzumab-DM1, a HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2⁺ metastatic breast cancer[J]. J Clin Oncol, 2010, 28: 2698-2704., articleTitle=A phase Ⅰ study of trastuzumab-DM1, a HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2⁺ metastatic breast cancer, refAbstract=null), Reference(id=1222469723305010102, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=null, pmid=null, pmcid=null, year=2008, volume=6, issue=null, pageStart=9280, pageEnd=9290, url=https://www.ncbi.nlm.nih.gov/pubmed/19010901, language=null, rfNumber=[32], rfOrder=31, authorNames=Lewis-Phillips GD, Li G, Dugger DL, journalName=Cancer Res, refType=null, unstructuredReference= Lewis-Phillips GD , Li G , Dugger DL . Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate[J]. Cancer Res, 2008, 6: 9280-9290., articleTitle=Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate, refAbstract=null), Reference(id=1222469723397284793, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1007/s12325-017-0519-6, pmid=null, pmcid=null, year=2017, volume=34, issue=null, pageStart=1015, pageEnd=1035, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=Lambert JM, Morris CQ, journalName=Adv Ther, refType=null, unstructuredReference= Lambert JM , Morris CQ . Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review[J]. Adv Ther, 2017, 34: 1015-1035., articleTitle=Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review, refAbstract=null), Reference(id=1222469723493753789, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=null, pmid=null, pmcid=null, year=2011, volume=4, issue=null, pageStart=741, pageEnd=749, url=http://d.old.wanfangdata.com.cn/Periodical/zgsyxyxzz201801031, language=null, rfNumber=[34], rfOrder=33, authorNames=Dijoseph JF, Dougher MM, Evans DY, journalName=Cancer Chemother Pharmacol, refType=null, unstructuredReference= Dijoseph JF , Dougher MM , Evans DY et al . Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP[J]. Cancer Chemother Pharmacol, 2011, 4: 741-749., articleTitle=Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP, refAbstract=null), Reference(id=1222469723548279743, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1146/annurev-med-050311-201823, pmid=null, pmcid=null, year=2013, volume=64, issue=null, pageStart=15, pageEnd=29, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=Sievers EL, Senter PD, journalName=Annu Rev Med, refType=null, unstructuredReference= Sievers EL , Senter PD . Antibody-drug conjugates in cancer therapy[J]. Annu Rev Med, 2013, 64: 15-29., articleTitle=Antibody-drug conjugates in cancer therapy, refAbstract=null), Reference(id=1222469723615388610, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1038/s41375-018-0210-1, pmid=null, pmcid=null, year=2018, volume=32, issue=null, pageStart=1768, pageEnd=1777, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=Kreitman RJ, Dearden C, Zinzani PL, journalName=Leukemia, refType=null, unstructuredReference= Kreitman RJ , Dearden C , Zinzani PL et al . Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia[J]. Leukemia, 2018, 32: 1768-1777., articleTitle=Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia, refAbstract=null), Reference(id=1222469723707663303, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=null, pmid=null, pmcid=null, year=2009, volume=114, issue=null, pageStart=2721, pageEnd=2729, url=http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=2f37b77c5f6451b3ac37e4989e0a3864, language=null, rfNumber=[37], rfOrder=36, authorNames=Dornan D, Bennett F, Chen Y, journalName=Blood, refType=null, unstructuredReference= Dornan D , Bennett F , Chen Y et al . Therapeutic potential of an anti-CD79b antibody drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma[J]. Blood, 2009, 114: 2721-2729., articleTitle=Therapeutic potential of an anti-CD79b antibody drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma, refAbstract=null), Reference(id=1222469723808326600, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1038/nbt832, pmid=null, pmcid=null, year=2003, volume=21, issue=null, pageStart=778, pageEnd=784, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=Doronina SO, Toki BE, Torgov MY, journalName=Nat Biotechnol, refType=null, unstructuredReference= Doronina SO , Toki BE , Torgov MY et al . Development of potent monoclonal antibody auristatin conjugates for cancer therapy[J]. Nat Biotechnol, 2003, 21: 778-784., articleTitle=Development of potent monoclonal antibody auristatin conjugates for cancer therapy, refAbstract=null), Reference(id=1222469723896406987, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1039/C8CS00676H, pmid=null, pmcid=null, year=2019, volume=48, issue=null, pageStart=4361, pageEnd=4374, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=Bargh JD, Isidro-Llobet A, Parker JS, journalName=Chem Soc Rev, refType=null, unstructuredReference= Bargh JD , Isidro-Llobet A , Parker JS . Cleavable linkers in antibody-drug conjugates[J]. Chem Soc Rev, 2019, 48: 4361-4374., articleTitle=Cleavable linkers in antibody-drug conjugates, refAbstract=null), Reference(id=1222469724005458899, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, doi=10.1158/1078-0432.CCR-11-1417, pmid=null, pmcid=null, year=2011, volume=17, issue=null, pageStart=6389, pageEnd=6397, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=Teicher BA, Chari RVJ, journalName=Clin Cancer Res, refType=null, unstructuredReference= Teicher BA , Chari RVJ . Antibody conjugate therapeutics: challenges and potential[J]. Clin Cancer Res, 2011, 17: 6389-6397., articleTitle=Antibody conjugate therapeutics: challenges and potential, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1222469716904501905, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, xref=null, ext=[AuthorCompanyExt(id=1222469716912890514, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=TOT Biopharm, Suzhou 215123, China), AuthorCompanyExt(id=1222469716917084819, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, companyId=1222469716904501905, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=东曜药业有限公司, 江苏 苏州 215123)])], figs=[ArticleFig(id=1222469719387530015, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=EN, label=null, caption=null, figureFileSmall=pFr6PyAi/A0jUmtqIWjrfA==, figureFileBig=PslrqQaCv0mwhvMI0WX6dg==, tableContent=null), ArticleFig(id=1222469719463027491, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=CN, label=Figure 1, caption= , figureFileSmall=pFr6PyAi/A0jUmtqIWjrfA==, figureFileBig=PslrqQaCv0mwhvMI0WX6dg==, tableContent=null), ArticleFig(id=1222469719672742703, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=EN, label=null, caption=null, figureFileSmall=TELUxJFEx+avAk8SNqiZsA==, figureFileBig=UJYgSqfcYzS7eEenuPKtKQ==, tableContent=null), ArticleFig(id=1222469719777600308, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=CN, label=Figure 2, caption= , figureFileSmall=TELUxJFEx+avAk8SNqiZsA==, figureFileBig=UJYgSqfcYzS7eEenuPKtKQ==, tableContent=null), ArticleFig(id=1222469719920206647, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=EN, label=null, caption=null, figureFileSmall=null, figureFileBig=null, tableContent=

Drug name	Company	Approved	Indication	Target
Mylotarg	Pfizer/Wyeth	2000 Approved 2010 Withdrawal 2017 Re-approved	Acute myeloid leukemia	CD33
Adcetris	Takeda/Seattle Genetice	2011 Approved	Hodgkin lymphoma, anaplastic large cell lymphoma	CD30
Kadcyla	Roche	2013 Approved	Metastatic breast cancer	HER2
Besponsa	Pfizer/Wyeth	2017 Approved	Acute lymphoblastic leukemia	CD22
Lumoxiti	Astrazeneca	2018 Approved	Hairy cell leukemia	CD22
Polivy	Roche	2019 Approved	Diffuse large B cell lymphoma	CD79b

), ArticleFig(id=1222469720008287036, tenantId=1146029695717560320, journalId=1189982191388893191, articleId=1222469715327443493, language=CN, label=Table 1, caption=

The global ADCs approved for use

, figureFileSmall=null, figureFileBig=null, tableContent=

Drug name	Company	Approved	Indication	Target
Mylotarg	Pfizer/Wyeth	2000 Approved 2010 Withdrawal 2017 Re-approved	Acute myeloid leukemia	CD33
Adcetris	Takeda/Seattle Genetice	2011 Approved	Hodgkin lymphoma, anaplastic large cell lymphoma	CD30
Kadcyla	Roche	2013 Approved	Metastatic breast cancer	HER2
Besponsa	Pfizer/Wyeth	2017 Approved	Acute lymphoblastic leukemia	CD22
Lumoxiti	Astrazeneca	2018 Approved	Hairy cell leukemia	CD22
Polivy	Roche	2019 Approved	Diffuse large B cell lymphoma	CD79b

)], attaches=null, journal=Journal(id=1189982048455397383, delFlag=0, nameCn=药学学报, nameEn=Acta Pharmaceutica Sinica, nameHistory1=null, nameHistory2=null, issn=0513-4870, eissn=null, cn=11-2163/R, coden=null, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=BTxjudbJDVO4PqdBR6On6Q==, journalPrice=null, startedYear=null, abbrevIsoEn=null, journalRemark=null, publicationField=null, createdTime=1761643429151, updatedTime=1788948913902, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Y, firstLetterEn=Y, subjectCode=Medical and Pharmaceutical Sciences, subjectName=Life Sciences, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=BTxjudbJDVO4PqdBR6On6Q==, picEn=c4l1ckL55nWbhl1KrFdWIA==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509553505227679, language=CN, name=药学学报, nameHistory1=null, nameHistory2=null, managedBy=中国科学技术协会, sponsoredBy=中国药学会、中国医学科学院药物研究所, publishedBy=《药学学报》编辑委员会编辑出版, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948914171, updatedTime=1788948914171, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=https://www.yxxb.com.cn/journalx_yxxb/authorLogOn.action, submissionEditorUrl=https://www.yxxb.com.cn/journalx_yxxb/editorLogOn.action, submissionReviewUrl=https://www.yxxb.com.cn/journalx_yxxb/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509553559753632, language=EN, name=Acta Pharmaceutica Sinica, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948914184, updatedTime=1788948914184, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=https://www.yxxb.com.cn/journalx_yxxb/authorLogOn.action, submissionEditorUrl=https://www.yxxb.com.cn/journalx_yxxb/editorLogOn.action, submissionReviewUrl=https://www.yxxb.com.cn/journalx_yxxb/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1189982191388893191, websiteList=[Website(id=1189982271588340489, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189982191388893191, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/yxxb/CN, language=CN, createTime=1761643482348, createBy=18614031015, updateTime=1761643498101, updateBy=18614031015, name=药学学报-中文, tplId=1146099689490845704, title=药学学报, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189982873114448678, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=articleTextType, value=kx, createTime=1761643625763, updateTime=1761643625763, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873093477155, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=banner, value=null, createTime=1761643625758, updateTime=1761643625758, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873135420201, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=grayFlag, value=0, createTime=1761643625768, updateTime=1761643625768, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873085088546, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=logo, value=https://castjournals.cast.org.cn/joweb/yxxb/CN/file/pic?fileId=w+t2v8bJnX5lh3+hRRJcDA==, createTime=1761643625756, updateTime=1761643625756, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873152197419, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=minRunFlag, value=0, createTime=1761643625772, updateTime=1761643625772, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873110254373, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/yxxb/CN/file/pic, createTime=1761643625762, updateTime=1761643625762, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873143808810, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=silenceFlag, value=0, createTime=1761643625770, updateTime=1761643625770, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873101865764, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1761643625760, updateTime=1761643625760, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873122837287, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=themeColor, value=null, createTime=1761643625765, updateTime=1761643625765, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982873127031592, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271588340489, code=themeStyle, value=null, createTime=1761643625766, updateTime=1761643625766, creator=18614031015, updator=18614031015)]), Website(id=1189982271655449355, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189982191388893191, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/yxxb/EN, language=EN, createTime=1761643482364, createBy=18614031015, updateTime=1761643514085, updateBy=18614031015, name=药学学报-英文, tplId=1146101810881728533, title=Acta Pharmaceutica Sinica, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189982903015633534, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=articleTextType, value=kx, createTime=1761643632892, updateTime=1761643632892, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902990467707, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=banner, value=null, createTime=1761643632886, updateTime=1761643632886, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903036605057, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=grayFlag, value=0, createTime=1761643632897, updateTime=1761643632897, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902982079098, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=logo, value=https://castjournals.cast.org.cn/joweb/yxxb/EN/file/pic?fileId=w+t2v8bJnX5lh3+hRRJcDA==, createTime=1761643632884, updateTime=1761643632884, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903053382275, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=minRunFlag, value=0, createTime=1761643632901, updateTime=1761643632901, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903007244925, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/yxxb/EN/file/pic, createTime=1761643632890, updateTime=1761643632890, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903044993666, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=silenceFlag, value=0, createTime=1761643632899, updateTime=1761643632899, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982902998856316, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1761643632888, updateTime=1761643632888, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903019827839, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=themeColor, value=null, createTime=1761643632893, updateTime=1761643632893, creator=18614031015, updator=18614031015), WebsiteProps(id=1189982903028216448, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189982271655449355, code=themeStyle, value=null, createTime=1761643632895, updateTime=1761643632895, creator=18614031015, updator=18614031015)])], journalTitle=药学学报, weixinUrl=null, journalUrl=https://www.yxxb.com.cn/aps, iacademicId=null, status=1, seqNo=null, journalTitleEn=Acta Pharmaceutica Sinica, journalPhotoCn=BTxjudbJDVO4PqdBR6On6Q==, journalPhotoEn=c4l1ckL55nWbhl1KrFdWIA==, journalFirstLetter=Y, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/yxxb/CN/10.16438/j.0513-4870.2019-0563, detailUrlEn=https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2019-0563, pdfUrlCn=https://castjournals.cast.org.cn/joweb/yxxb/CN/PDF/10.16438/j.0513-4870.2019-0563, pdfUrlEn=https://castjournals.cast.org.cn/joweb/yxxb/EN/PDF/10.16438/j.0513-4870.2019-0563, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=1, orderTime=1570809600000, fullTextJson=null, articleText=null, reference=null)